Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II crossover study of RPL554 plus bronchodilators in COPD
2015-002536-41Phase 2Completed
- Sponsor
- Verona Pharma
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ensifentrine in chronic obstructive pulmonary disease (COPD), sponsored by Verona Pharma. Primary endpoints: Peak FEV1 over 8 hours and AUC FEV1 over 8 hours. Started Jul 2015; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2015-002536-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002536-41.